Janus kinase inhibition and symptom control in myeloproliferative neoplasms.
作者信息
Bose Prithviraj, Swaminathan Mahesh
机构信息
a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
出版信息
Curr Med Res Opin. 2018 May;34(5):935-937. doi: 10.1080/03007995.2018.1438999. Epub 2018 Mar 12.
Abstract
摘要
相似文献
1
Janus kinase inhibition and symptom control in myeloproliferative neoplasms.Janus激酶抑制与骨髓增殖性肿瘤的症状控制
Curr Med Res Opin. 2018 May;34(5):935-937. doi: 10.1080/03007995.2018.1438999. Epub 2018 Mar 12.
2
Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment.芦可替尼：自身免疫性骨髓纤维化治疗的一种新的一线策略。
Leuk Lymphoma. 2023 Oct;64(10):1723-1726. doi: 10.1080/10428194.2023.2234526. Epub 2023 Jul 13.
3
Chronic myeloproliferative disorders: is quality-of-life the new goal?慢性骨髓增殖性疾病：生活质量是新目标吗？
Curr Med Res Opin. 2018 Jul;34(7):1345-1347. doi: 10.1080/03007995.2018.1473245. Epub 2018 Jun 1.
4
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.JAK抑制剂在骨髓纤维化管理中的应用：英国血液学标准委员会2012年骨髓纤维化调查与管理指南的修订版
Br J Haematol. 2014 Nov;167(3):418-20. doi: 10.1111/bjh.12985. Epub 2014 Jun 25.
5
Ruxolitinib: the first agent approved for myelofibrosis.芦可替尼：首个获批用于治疗骨髓纤维化的药物。
Clin Adv Hematol Oncol. 2012 Feb;10(2):111-3.
6
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.用于治疗骨髓纤维化的Janus激酶1和Janus激酶2抑制剂。
Cochrane Database Syst Rev. 2015 Apr 10;2015(4):CD010298. doi: 10.1002/14651858.CD010298.pub2.
7
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.Janus 激酶抑制剂治疗骨髓增殖性肿瘤的研究进展：文献更新。
Expert Opin Pharmacother. 2024 Jul;25(10):1391-1404. doi: 10.1080/14656566.2024.2385729. Epub 2024 Aug 1.
8
Extramedullary haematopoiesis within hepatic sinusoids of a patient with primary myelofibrosis.原发性骨髓纤维化患者肝血窦内的髓外造血。
Br J Haematol. 2022 Mar;196(5):1130. doi: 10.1111/bjh.17923. Epub 2021 Nov 18.
9
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.芦可替尼与最佳可用疗法对骨髓纤维化患者骨髓纤维化的长期影响。
J Hematol Oncol. 2018 Mar 15;11(1):42. doi: 10.1186/s13045-018-0585-5.
10
Ruxolitinib for the treatment of myelofibrosis.芦可替尼用于治疗骨髓纤维化。
Drugs Today (Barc). 2011 Nov;47(11):817-27. doi: 10.1358/dot.2011.47.11.1708829.
引用本文的文献
1
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.JAK/STAT3 是富含基质的结直肠癌患者的治疗靶点。
J Exp Clin Cancer Res. 2024 Mar 1;43(1):64. doi: 10.1186/s13046-024-02958-4.
本文引用的文献
1
Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.芦可替尼治疗对日本骨髓纤维化患者生活质量的影响。
Curr Med Res Opin. 2018 Mar;34(3):531-537. doi: 10.1080/03007995.2017.1415874. Epub 2018 Jan 4.
2
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.芦可替尼对比最佳可用疗法用于对羟基脲不耐受或耐药的真性红细胞增多症
Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9.
3
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.SIMPLIFY-1：一项在初治的骨髓纤维化患者中比较莫洛替尼与芦可替尼的III期随机试验。
J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.
4
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.芦可替尼用于对羟基脲难治或不耐受的原发性血小板增多症：长期2期研究结果
Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21.
5
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.骨髓增殖性肿瘤（MPN）对患者生活质量和生产力的影响：国际MPN里程碑式调查结果
Ann Hematol. 2017 Oct;96(10):1653-1665. doi: 10.1007/s00277-017-3082-y. Epub 2017 Aug 5.
6
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.芦可替尼停药后骨髓纤维化的克隆进化与结局
Blood. 2017 Aug 31;130(9):1125-1131. doi: 10.1182/blood-2017-05-783225. Epub 2017 Jul 3.
7
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.鲁索替尼治疗临床获益的实用衡量指标：COMFORT-I的探索性分析
Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):479-487. doi: 10.1016/j.clml.2017.05.015. Epub 2017 May 12.
8
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.在既往接受过鲁索替尼治疗的骨髓纤维化患者中使用Janus激酶2抑制剂非格司亭（JAKARTA-2）：一项单臂、开放标签、非随机、2期、多中心研究。
Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.
9
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.帕西替尼与最佳可用疗法治疗无论基线血细胞减少情况如何的骨髓纤维化（PERSIST-1）：一项国际随机3期试验
Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20.
10
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.芦可替尼用于骨髓纤维化患者的长期治疗：来自随机、双盲、安慰剂对照3期COMFORT-I试验的5年更新数据
J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.
Zotero 插件